Literature DB >> 21950644

Adjunct mirtazapine for negative symptoms of schizophrenia.

Stephanie V Phan1, Tiffany-Jade M Kreys.   

Abstract

Negative symptoms of schizophrenia are characterized by affective flattening, alogia, avolition, and anhedonia and are often nonresponsive to antipsychotic therapy. Because negative symptoms are predictive of poor occupational and social functioning, as well as poor global outcomes, numerous studies evaluating adjunct therapy to antipsychotics have been conducted. This review focuses on the use of the antidepressant mirtazapine as adjunct therapy to antipsychotics for the treatment of negative symptoms of schizophrenia. A literature search of the MEDLINE database (from inception-March 2011) identified eight relevant articles: six were randomized, double-blind, placebo-controlled trials, and two were open-label trials. Of the six randomized trials reviewed, four studies assessed add-on mirtazapine to second-generation antipsychotics, whereas two studies examined add-on mirtazapine to first-generation antipsychotics. Five of the six randomized trials supported the use of mirtazapine for negative symptoms of schizophrenia. Of the two open-label trials, one naturalistic study demonstrated that mirtazapine add-on therapy to clozapine was not associated with improvements in negative symptoms; however, this study focused primarily on improvements in cognition, not negative symptoms. An open-label extension phase to a randomized controlled trial showed that mirtazapine continued to produce significant improvement in negative symptoms over a longer duration of time, when added to first-generation antipsychotic therapy. Overall, mirtazapine appears to be well tolerated and associated with few drug interactions. Although adjunct mirtazapine to antipsychotics has been shown to be effective at doses of 30 mg/day in most of the trials, limitations of these studies include short study duration and small sample sizes. To improve generalizability, larger multicenter studies with broader inclusion criteria should be conducted. In addition, studies of longer duration that use different mirtazapine dosages are needed to further assess the benefits of mirtazapine for negative symptoms of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21950644     DOI: 10.1592/phco.31.10.1017

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  3 in total

Review 1.  Pharmacogenomics can improve antipsychotic treatment in schizophrenia.

Authors:  Qingqing Xu; Xi Wu; Yuyu Xiong; Qinghe Xing; Lin He; Shengying Qin
Journal:  Front Med       Date:  2013-04-21       Impact factor: 4.592

Review 2.  Mirtazapine adjunct for people with schizophrenia.

Authors:  Luke A Perry; Dhruvesh Ramson; Suzanne Stricklin
Journal:  Cochrane Database Syst Rev       Date:  2018-05-26

3.  Assessing the risk for suicide in schizophrenia according to migration, ethnicity and geographical ancestry.

Authors:  Nuwan C Hettige; Ali Bani-Fatemi; James L Kennedy; Vincenzo De Luca
Journal:  BMC Psychiatry       Date:  2017-02-09       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.